Skip to content

Adjuvant Transarterial Chemoembolization for Intermediate Stage Hepatocellular Carcinoma with Microvascular Invasion

Adjuvant Transarterial Chemoembolization for Intermediate Stage Hepatocellular Carcinoma with Microvascular Invasion

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300071111
Enrollment
Unknown
Registered
2023-05-05
Start date
2023-05-10
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Interventions

liver resection+TACE group:No
liver resection group:No

Sponsors

Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients who met the following criteria were enrolled: (1) age 18 to 80 years; (2) patients with intermediate-stage HCC (BCLC stage B) with MVI, where MVI was diagnosed by postoperative pathology; (3) curative liver resection (complete resection of the tumor without any tumor tissue at the cutting edge); (4) no macrovascular invasion; (5) without any preoperative anticancer treatments; (6) Child-Pugh class A or B; (7) no history of other malignancies;

Exclusion criteria

Exclusion criteria: Patients were excluded from the analysis for any of the following reasons: (1) HCC patients with MVI negative; (2) recurrent HCC; (3) received preoperative adjuvant therapy; (4) early-stage HCC (BCLC stage 0-A); (5) incomplete clinical data; (6) lost to follow-up within 3 months after treatment.

Design outcomes

Primary

MeasureTime frame
overall survival;

Secondary

MeasureTime frame
recurrence-free survival;

Countries

China

Contacts

Public ContactXiaohui Wang

Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University)

xiaohuiwang21@163.com+86 15692436948

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026